Alectinib - CAS 1256580-46-7
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Alectinib
Catalog Number:
B0084-454466
Synonyms:
AF 802; AF802; AF-802; CH5424802; CH-5424802; CH 5424802; RO5424802; RO 5424802; RO-5424802.
CAS Number:
1256580-46-7
Description:
Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK. CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth. Results support the potential for clinical evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.
COA:
Inquire
MSDS:
Inquire
Targets:
ALK
Current Developer:
Chugai Pharmaceutical Co., Ltd
Catalog Number Size Price Stock Quantity
B0084-454466 200 mg $199 In stock
Bulk Inquiry
Chemical Structure
CAS 1256580-46-7 Alectinib

Related ALK Products


BAY-754

BAY-754 is an ALK-1 inhibitor used as an anti-angiogenesis agent. It inhibited the eye vascular leakage in dose manner in mouse model.

CAS 1432597-26-6 LDN-212854

LDN-212854
(CAS: 1432597-26-6)

LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2. LDN-212854 exhibits some selectivity for ALK2 in preference to other...

CAS 1391712-60-9 CEP-37440

CEP-37440
(CAS: 1391712-60-9)

CEP-37440 is an orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with po...

CAS 1032900-25-6 Ceritinib

Ceritinib
(CAS: 1032900-25-6)

This active molecular is a selective inhibitor of ALK(anaplastic lymphoma kinase)which is a target found in NSCLC (metastatic non-small cell lung cancer). The I...

CAS 1256589-74-8 CH5424802 Hydrochloride

CH5424802 Hydrochloride
(CAS: 1256589-74-8)

CH5424802 Hcl (AF 802 Hcl; Alectinib Hcl) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.

CAS 356559-13-2 SB-505124 hydrochloride

SB-505124 hydrochloride
(CAS: 356559-13-2)

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptor ALK5 and as well as being a selective inhibitor of ALK4 but with less pote...

CAS 1627503-67-6 LDN-214117

LDN-214117
(CAS: 1627503-67-6)

LDN-214117 is a selective and potent ALK2 inhibitor. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM. There are currently no effective therapi...

CAS 1415560-69-8 Crizotinib hydrochloride

Crizotinib hydrochloride
(CAS: 1415560-69-8)

Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK. Crizotinib inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM). Crizotinib is use...

CAS 1454846-35-5 PF-06463922

PF-06463922
(CAS: 1454846-35-5)

PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), wi...

CAS 1356962-34-9 HG-14-10-04

HG-14-10-04
(CAS: 1356962-34-9)

HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.

CAS 1022958-60-6 CEP-28122

CEP-28122
(CAS: 1022958-60-6)

CEP-28122 is a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers...

Brigatinib (AP-26113)
(CAS: 1197953-54-0)

Brigatinib, is an orally active, also known as AP-26113, potent and selective Dual ALK/EGFR inhibitor. AP26113 binds to and inhibits ALK kinase(ALK belongs to t...

CAS 761438-38-4 ALK inhibitor 2

ALK inhibitor 2
(CAS: 761438-38-4)

ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.

CAS 1062368-49-3 ML347

ML347
(CAS: 1062368-49-3)

ML347 is a selective BMP receptor inhibitor with IC50 of 32 nM for ALK2, >300-fold selectivity over ALK3. Also inhibits ALK1 activity with IC50 of 46 nM.

CAS 1380575-43-8 LDK378 dihydrochloride

LDK378 dihydrochloride
(CAS: 1380575-43-8)

Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). In Phase I trials, LDK378 s...

Entrectinib (RXDX-101)
(CAS: 1108743-60-7)

Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.

CAS 1197958-12-5 AP-26113

AP-26113
(CAS: 1197958-12-5)

AP26113 is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with pote...

CAS 1256580-46-7 Alectinib

Alectinib
(CAS: 1256580-46-7)

Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing ...

CAS 1097917-15-1 ASP-3026

ASP-3026
(CAS: 1097917-15-1)

ASP3026 is a novel and selective inhibitor for the ALK kinase. ASP3026 potently inhibited ALK kinase activity and was more selective than crizotinib in a Tyr-ki...

CAS 1116235-97-2 GSK1838705A

GSK1838705A
(CAS: 1116235-97-2)

GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively. GSK1838705A blocks ...

Reference Reading


1.Rapid and dramatic response to alectinib in an ALK rearranged non-small-cell lung cancer patient who are critically ill.
Yoshida T1, Hida T, Yatabe Y. Anticancer Drugs. 2016 Mar 2. [Epub ahead of print]
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have shown promising clinical activity in the treatment of non-small-cell lung cancer (NSCLC) that harbors ALK rearrangement. The next-generation ALK-TKI, alectinib, has been reported to have potent efficacy in ALK-positive NSCLC patients including on mutations that confer resistance to crizotinib, which was the first ALK-TKI approved for ALK-positive NSCLC. The efficacy and safety of ALK-TKIs, including crizotinib and alectinib, as the first-line treatment in critically ill patients is unclear. We report one ALK-positive NSCLC patient with poor performance status (PS) and disseminated intravascular coagulation because of respiratory failure and multiple metastases, and experienced the rapid and dramatic response to alectinib without adverse events that can lead to discontinuation and dose reduction of the drug. After a couple of months of treatment with alectinib, radiological review indicated a complete response.
2.Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging.
Aikawa H1, Hayashi M1,2, Ryu S2, Yamashita M2, Ohtsuka N3, Nishidate M2,4,5, Fujiwara Y6, Hamada A1,2,5. Sci Rep. 2016 Mar 30;6:23749. doi: 10.1038/srep23749.
In the development of anticancer drugs, drug concentration measurements in the target tissue have been thought to be crucial for predicting drug efficacy and safety. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is commonly used for determination of average drug concentrations; however, complete loss of spatial information in the target tissue occurs. Mass spectrometry imaging (MSI) has been recently applied as an innovative tool for detection of molecular distribution of pharmacological agents in heterogeneous targets. This study examined the intra-brain transitivity of alectinib, a novel anaplastic lymphoma kinase inhibitor, using a combination of matrix-assisted laser desorption ionization-MSI and LC-MS/MS techniques. We first analyzed the pharmacokinetic profiles in FVB mice and then examined the effect of the multidrug resistance protein-1 (MDR1) using Mdr1a/b knockout mice including quantitative distribution of alectinib in the brain.
3.Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X1, Fernandez-Salas E2, Li E3, Wang S4. Neoplasia. 2016 Mar;18(3):162-71. doi: 10.1016/j.neo.2016.02.001.
Crizotinib is the first anaplastic lymphoma kinase (ALK) inhibitor to have been approved for the treatment of non-small cell lung cancer (NSCLC) harboring an ALK fusion gene, but it has been found that, in the clinic, patients develop resistance to it. Alectinib and ceritinib are second-generation ALK inhibitors which show remarkable clinical responses in both crizotinib-naive and crizotinib-resistant NSCLC patients harboring an ALK fusion gene. Despite their impressive activity, clinical resistance to alectinib and ceritinib has also emerged. In the current study, we elucidated the resistance mechanisms to these second-generation ALK inhibitors in the H3122 NSCLC cell line harboring the EML4-ALK variant 1 fusion in vitro. Prolonged treatment of the parental H3122 cells with alectinib and ceritinib led to two cell lines which are 10 times less sensitive to alectinib and ceritinib than the parental H3122 cell line. Although mutations of ALK in its kinase domain are a common resistance mechanism for crizotinib, we did not detect any ALK mutation in these resistant cell lines.
4.Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Tanaka H1, Taima K2, Morimoto T2, Nakamura K2, Tanaka Y2, Itoga M3, Takanashi S4, Okumura K2. BMC Res Notes. 2016 Mar 17;9(1):173. doi: 10.1186/s13104-016-1983-9.
BACKGROUND: Lung cancers with anaplastic lymphoma kinase rearrangements are highly sensitive to anaplastic lymphoma kinase tyrosine kinase inhibition, underscoring the notion that such cancers are addicted to anaplastic lymphoma kinase activity. Several anaplastic lymphoma kinase inhibitors have been identified and are being evaluated in clinical trials. However patients with poor performance status (3 or 4) were not involved in these clinical trials, it has been unclear to use anaplastic lymphoma kinase-tyrosine kinase inhibitors for these patients. Here, we report an anaplastic lymphoma kinase-positive non small cell lung cancer patient with performance status 4, who was successfully treated with alectinib.